Covered recipient · General Payments record
SAMANTHA HINDS CAMPA
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$2,122.73
- Reported across 114 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $442.04 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $221.01 | 6 |
| DEXCOM, INC. | $44.41 | 2 |
| Novo Nordisk AS | $36.78 | 2 |
| PFIZER INC. | $36.15 | 2 |
| Acerta Pharma LLC | $24.08 | 1 |
| Medtronic, Inc. | $23.18 | 1 |
| Astellas Pharma US Inc | $21.44 | 1 |
| ABBVIE INC. | $20.32 | 1 |
| Amgen Inc. | $14.67 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $20.32 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103920903 | CMS |
| Amgen Inc. | $14.67 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117579186 | CMS |
| Astellas Pharma US Inc | $21.44 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139413697 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.08 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104699417 | CMS |
| Dexcom, Inc. | $22.93 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153333643 | CMS |
| Dexcom, Inc. | $21.48 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153333645 | CMS |
| GlaxoSmithKline, LLC. | $13.61 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116624831 | CMS |
| GlaxoSmithKline, LLC. | $120.91 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116630520 | CMS |
| GlaxoSmithKline, LLC. | $23.97 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116296903 | CMS |
| GlaxoSmithKline, LLC. | $22.29 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116260852 | CMS |
| GlaxoSmithKline, LLC. | $20.67 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116611531 | CMS |
| GlaxoSmithKline, LLC. | $19.56 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116455095 | CMS |
| Medtronic, Inc. | $23.18 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117056925 | CMS |
| Novo Nordisk Inc | $18.39 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097655877 | CMS |
| Novo Nordisk Inc | $18.39 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096874696 | CMS |
| PFIZER INC. | $22.50 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131398600 | CMS |
| PFIZER INC. | $13.65 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131398313 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.